Richard Silver, MD, Weill Cornell Medical College, New York, NY, highlights the mechanism of action of rusfertide in polycythemia vera (PV), outlining the advantages of this drug. Prof. Silver explains that rusfertide treatment reduces and could even eliminate the need for phlebotomy in these patients. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.